medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2024, Number 1

<< Back Next >>

Arch Neurocien 2024; 29 (1)

An unusual diffuse CD34 staining in an olfractory groove cellular schwannoma: case report

Theologou M, Perez-Ruiz J, Varoutis P, Flaris N, Skoulios N

Language: English
References: 19
Page: 15-19
PDF size: 484.26 Kb.


ABSTRACT

Background: Intracranial schwannomas are benign lesions, expected to exhibit characteristic ultrastructural features and immunophenotypic profile, typically being S-100, SOX10 and collagen-IV positive, while other markers, including CD34, are not usually expressed and are employed in the diagnostic elimination process.
Case presentation: A 51-year-old female presented with a rapidly deteriorating neurological status. MRI showed a heterogeneous enhancing neoplasm of the anterior fossa. Preoperative differential diagnosis predilected an esthesioneuroblastoma. A bifrontal craniotomy with total excision of the lesion was performed. Dural infiltration was present. There was no association with the olfactory system. Microscopic examination revealed a uniform population of spindled to slightly epithelioid cellular proliferation with no significant atypia, low mitotic activity, and foci of necrosis. Upon immunohistochemical investigation the tumor was consistent with cellular schwannoma. Diffuse positivity for CD34 was an unusual finding.
Discussion: Cellular schwannoma should be considered in the presence of an anterior fossa tumefaction. Olfactory nerve is not directly associated with these lesions. Various theories have been proposed, with the meningeal trigeminal branches’ origin being the most probable. The characteristic ultrastructural Antoni formations may be scarce or even absent in cellular schwannomas creating potential diagnostic difficulties. Unusual diffuse CD34 positivity should not be employed for excluding the diagnosis.


REFERENCES

  1. Machinis TG, Fountas KN, Dimopoulos V, Robinson JS. History ofacoustic neurinoma surgery. Neurosurg Focus. 2005;18(4):e9.

  2. Figueiredo EG, Soga Y, Amorim RL, Oliveira AM, Teixeira MJ.The puzzling olfactory groove schwannoma: a systematic review.Skull Base. 2011;21(1):31-6.

  3. Park JY, Park H, Park NJ, Park JS, Sung H-J, Lee SS. Use ofCalretinin, CD56, and CD34 for Differential Diagnosis ofSchwannoma and Neurofibroma. The Korean Journal ofPathology. 2011; 45(1).

  4. Ohashi R, Wakayama N, Kawamoto M, Tsuchiya S, Okubo K.Solitary nasal schwannoma: Usefulness of CD34 and calretininstaining for distinction from histological mimics. J Nippon MedSch. 2013; 80(4):300-6.

  5. Hirose T, Tani T, Shimada T, Ishizawa K, Shimada S, Sano T.Immunohistochemical demonstration of EMA/Glut1-positiveperineurial cells and CD34-positive fibroblastic cells in peripheralnerve sheath tumors. Mod Pathol. 2003; 16(4):293-8.

  6. Masuda H, Nemoto M, Okonogi S, Node Y, Ando S, KondoK, et al. Utility of Schwann/2E and Sox10 in distinguishingCD57-negative olfactory groove schwannoma from olfactoryensheathing cell tumor: A case report and review of the literature.Neuropathology. 2020;40(4):373-8.

  7. Kasymov AR, Rzaev DA, Kalinovsky AV, Voronina EI. Olfactory(subfrontal) schwannoma: case report and literature review. ZhVopr Neirokhir Im N N Burdenko. 2022;86(3):50-5.

  8. Liu S, Liu S, Liu Q, Yu L, Yu P, Sun S, et al. Schwannoma inthe Olfactory Groove: Two Case Reports. Ear Nose Throat J.2022:1455613221139405.

  9. Sauvaget F, Francois P, Ben Ismail M, Thomas C, Velut S.Anterior fossa schwannoma mimicking an olfactory groovemeningioma: case report and literature review. Neurochirurgie.2013;59(2):75-80.

  10. Murtaza M, Chacko A, Delbaz A, Reshamwala R, Rayfield A,McMonagle B, et al. Why are olfactory ensheathing cell tumorsso rare? Cancer Cell Int. 2019;19:260.

  11. Russel DSR. Pathology of Tumors of the Nervous System. 3rd ed:London: E Arnold; 1971.

  12. D'Almeida Costa F, Dias TM, Lombardo KA, Raghunathan A,Giannini C, Kenyon L, et al. Intracranial cellular schwannomas:a clinicopathological study of 20 cases. Histopathology.2020;76(2):275-82.

  13. Perry A, Reus D, Rodriguez F. Neurofibroma. In: Tumors STaB,editor. WHO Classification of Tumors 5th ed: WHO; 2019. p.232-6.

  14. Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology ofperipheral nerve sheath tumors: diagnostic overview andupdate on selected diagnostic problems. Acta Neuropathol.2012;123(3):295-319.

  15. Chaubal A, Paetau A, Zoltick P, Miettinen M. CD34immunoreactivity in nervous system tumors. Acta Neuropathol.1994;88(5):454-8.

  16. Tosaka M, Hirato J, Miyagishima T, Saito N, Nakazato Y, SasakiT. Calcified vestibular schwannoma with unusual histologicalcharacteristics - positive immunoreactivity for CD-34 antigen.Acta Neurochir (Wien). 2002;144(4):395-9.

  17. Khalifa MA, Montgomery EA, Ismiil N, Azumi N. What are theCD34+ cells in benign peripheral nerve sheath tumors? Doubleimmunostaining study of CD34 and S-100 protein. Am J ClinPathol. 2000;114(1):123-6.

  18. Weiss SW, Nickoloff BJ. CD-34 Is Expressed by a DistinctiveCell Population in Peripheral Nerve, Nerve Sheath Tumors, andRelated Lesions. The American Journal of Surgical Pathology. 1993;17(10):1039-45.

  19. Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, ViskochilDH. Malignant peripheral nerve sheath tumor: a comparisonof grade, immunophenotype, and cell cycle/growth activationmarker expression in sporadic and neurofibromatosis 1-relatedlesions. Am J Surg Pathol. 2003;27(10):1337-45.




2020     |     www.medigraphic.com